Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 20Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Transitional Cell Carcinoma of the Bladder 1Non-metastatic Muscle Invasive Bladder Cancer 1Infiltrating Bladder Urothelial Carcinoma 1Cone Dystrophy 3 1Carcinoma, Transitional Cell 1Bladder Adenocarcinoma 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × Cystectomy × Clear all
NCT06184516 2025-09-15

Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy

University of Florida

Phase 2 Recruiting
147 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡